Dynasil Corporation of America (DYSL) 10-Q 13 Aug 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Jun. 30, 2014	Aug. 05, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'DYNASIL CORP OF AMERICA	'
Entity Central Index Key	'0000030831	'
Current Fiscal Year End Date	'--09-30	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'DYSL	'
Entity Common Stock, Shares Outstanding	'	16,327,896

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Jun. 30, 2014	Sep. 30, 2013
Current Assets	'	'
Cash and cash equivalents	$3,085,154	$2,436,828
Accounts receivable, net of allowances of $284,743 and $184,775 at June 30, 2014 and September 30, 2013, respectively	3,282,400	3,657,320
Costs in excess of billings and unbilled receivables	1,468,741	1,537,318
Inventories, net of reserves	2,941,358	3,140,244
Prepaid expenses and other current assets	1,393,411	1,291,942
Total current assets	12,171,064	12,063,652
Property, Plant and Equipment, net	6,592,839	4,773,779
Other Assets	'	'
Intangibles, net	1,333,513	3,484,583
Goodwill	6,332,396	6,240,983
Deferred financing costs, net	41,804	114,229
Total other assets	7,707,713	9,839,795
Total Assets	26,471,616	26,677,226
Current Liabilities	'	'
Current portion of long-term debt	2,437,742	9,819,048
Capital lease obligations, current	128,979	124,383
Accounts payable	2,230,015	2,056,262
Deferred revenue	127,445	515,790
Accrued expenses and other liabilities	2,652,362	2,846,850
Total current liabilities	7,576,543	15,362,333
Long-term Liabilities	'	'
Long-term debt, net of current portion	3,254,443	0
Capital lease obligations, net of current portion	131,269	232,173
Convertible notes	810,413	0
Pension liability	249,966	249,966
Deferred tax liability	179,369	186,866
Total long-term liabilities	4,625,460	669,005
Stockholders' Equity	'	'
Common Stock, $0.0005 par value, 40,000,000 shares authorized, 17,104,204 and 16,224,402 shares issued, 16,294,044 and 15,414,242 shares outstanding at June 30, 2014 and September 30, 2013, respectively.	8,552	8,112
Additional paid in capital	19,127,446	17,476,003
Accumulated other comprehensive income	367,642	152,685
Accumulated deficit	-4,201,139	-6,004,570
Less 810,160 shares of treasury stock - at cost	-986,342	-986,342
Total Dynasil stockholders' equity	14,316,159	10,645,888
Noncontrolling interest	-46,546	0
Total stockholders' equity	14,269,613	10,645,888
Total Liabilities and Stockholders' Equity	$26,471,616	$26,677,226

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] (USD $)	Jun. 30, 2014	Sep. 30, 2013
Allowance for doubtful accounts (in dollars)	$284,743	$184,775
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	17,104,204	16,224,402
Common stock, shares outstanding	16,294,044	15,414,242
Treasury stock, shares	810,160	810,160

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net revenue	$10,640,527	$11,322,342	$31,758,512	$32,360,147
Cost of revenue	6,732,880	6,622,392	19,041,451	18,512,430
Gross profit	3,907,647	4,699,950	12,717,061	13,847,717
Operating expenses:	'	'	'	'
Sales and marketing	337,033	418,318	1,046,567	1,384,739
Research and development	300,296	499,732	1,024,873	1,710,090
General and administrative	3,144,132	3,997,407	9,624,678	11,644,624
Impairment of goodwill and long-lived assets	0	0	0	6,763,072
Total operating expenses	3,781,461	4,915,457	11,696,118	21,502,525
Gain on sale of assets	30,000	0	1,216,686	0
Income (loss) from operations	156,186	-215,507	2,237,629	-7,654,808
Interest expense, net	145,797	181,773	567,904	545,690
Income (loss) before taxes	10,389	-397,280	1,669,725	-8,200,498
Income tax (credit) provision	-47,719	-30,920	-87,160	-213,065
Net income (loss)	58,108	-366,360	1,756,885	-7,987,433
Less: Net loss attributable to noncontrolling interest	-16,059	0	-46,546	0
Net income (loss) attributable to common stockholders	74,167	-366,360	1,803,431	-7,987,433
Net income (loss)	58,108	-366,360	1,756,885	-7,987,433
Other comprehensive income (loss):	'	'	'	'
Foreign currency translation	141,948	-45	214,957	-245,666
Total comprehensive income (loss)	$200,056	($366,405)	$1,971,842	($8,233,099)
Basic net income (loss) per common share (in dollars per share)	$0	($0.02)	$0.12	($0.54)
Diluted net income (loss) per common share (in dollars per share)	$0	($0.02)	$0.12	($0.54)
Weighted average shares outstanding	'	'	'	'
Basic (in shares)	15,280,607	14,859,899	15,134,377	14,767,401
Diluted (in shares)	15,299,422	14,859,899	15,145,639	14,767,401

CONSOLIDATED_STATEMENTS_OF_CHA

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Retained Earnings [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]
Balance at Sep. 30, 2013	$10,645,888	$8,112	$17,476,003	$152,685	($6,004,570)	($986,342)	$0
Balance (in shares) at Sep. 30, 2013	'	16,224,402	'	'	'	810,160	'
Issuance of shares of common stock under employee stock purchase plan	10,544	4	10,540	0	0	0	0
Issuance of shares of common stock under employee stock purchase plan (in shares)	'	8,373	'	'	'	0	'
Stock-based compensation costs	402,339	86	402,253	0	0	0	0
Stock-based compensation costs (in shares)	'	171,429	'	'	'	0	'
Issuance of shares for acquisition	1,239,000	350	1,238,650	0	0	0	0
Issuance of shares for acquisition (in shares)	'	700,000	'	'	'	0	'
Foreign currency translation adjustment	214,957	0	0	214,957	0	0	0
Net income (loss)	1,756,885	0	0	0	1,803,431	0	-46,546
Balance at Jun. 30, 2014	$14,269,613	$8,552	$19,127,446	$367,642	($4,201,139)	($986,342)	($46,546)
Balance (in shares) at Jun. 30, 2014	'	17,104,204	'	'	'	810,160	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net income (loss)	$1,756,885	($7,987,433)
Adjustments to reconcile net income (loss) to net cash:	'	'
Stock compensation expense	402,339	300,642
Foreign exchange loss (gain)	29,732	-33,526
Gain on sale of assets	-1,216,686	-87,803
Depreciation and amortization	809,303	1,329,401
Other	80,787	-104,739
Impairment of goodwill and long-lived assets	0	6,763,072
Other changes in assets and libilities:	'	'
Accounts receivable, net	-70,197	1,496,979
Inventories	-491,722	-49,887
Costs in excess of billings and unbilled receivables	68,577	177,391
Prepaid expenses and other assets	-110,767	-27,769
Accounts payable	185,311	206,012
Accrued expenses and other liabilities	64,672	-705,372
Deferred revenue	-382,184	-160,058
Net cash from operating activities	1,126,050	1,116,910
Cash flows from investing activities:	'	'
Acquisitions	-500,000	0
Proceeds from sale of assets	4,357,219	80,252
Purchases of property, plant and equipment	-879,303	-422,577
Net cash from investing activities	2,977,916	-342,325
Cash flows from financing activities:	'	'
Proceeds from issuance of common stock	10,544	16,498
Net proceeds from issuance of convertible notes	810,413	0
Principal payments on capital leases	-96,308	-49,797
Proceeds from short and long-term debt	2,707,261	0
Payments on long-term debt	-6,841,018	-1,401,158
Net cash from financing activities	-3,409,108	-1,434,457
Effect of exchange rates on cash and cash equivalents	-46,532	23,357
Net change in cash and cash equivalents	648,326	-636,515
Cash and cash equivalents, beginning	2,436,828	3,414,880
Cash and cash equivalents, ending	3,085,154	2,778,365
Non cash activities:	'	'
Assets acquired	1,739,000	0
Less: common shares issued in acquisition as consideration	1,239,000	0
Cash paid in acquisition	500,000	0
Assets purchased under capital leases	$0	$432,953

Basis_of_Presentation_and_Abil

Basis of Presentation and Ability to Continue as a Going Concern	9 Months Ended
	Jun. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Operations [Text Block]	'
	Note 1 - Basis of Presentation and Ability to Continue as a Going Concern
	The accompanying consolidated balance sheet as of June 30, 2014, the consolidated statements of operations and comprehensive income (loss) for the three months and nine months ended June 30, 2014 and 2013, changes in stockholders’ equity for the nine months ended June 30, 2014 and cash flows for the nine months ended June 30, 2014 and 2013 of Dynasil Corporation of America and subsidiaries (“Dynasil” or the “Company”), and the related information contained in these notes have been prepared by management and are unaudited. Certain prior year balances have been reclassified to conform to the current year presentation. These reclassifications did not affect previously reported net loss or stockholders’ deficit. In the opinion of management, all adjustments (which include normal recurring and nonrecurring items) necessary to present fairly the financial position, results of operations and cash flows in conformity with generally accepted accounting principles for the periods presented have been made. Interim operating results are not necessarily indicative of operating results for a full year.
	The preparation of unaudited consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Certain information and note disclosures normally included in the Company's annual financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. These consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company's September 30, 2013 Annual Report on Form 10-K previously filed by the Company with the Securities and Exchange Commission.
	The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company incurred substantial losses from operations for the fiscal years ended September 30, 2013 and 2012 and failed to comply with the financial covenants set forth in the terms of its outstanding loan agreements for the fiscal year ended September 30, 2012 and each of the quarters during the fiscal year ended September 30, 2013. These covenants required the Company to maintain specified ratios of earnings before interest, taxes, depreciation and amortization (EBITDA) to fixed charges and to total/senior debt.
	The Company returned to profitability for the three month period ended December 31, 2013 and regained compliance with the financial covenants described above. However Santander Bank, N.A. (“Santander”), the Company’s former senior lender, continued to require that it not pay interest due monthly to its subordinated lender, Massachusetts Capital Resource Company (“MCRC”), constituting a separate event of default. In addition, Santander advised the Company that it was unwilling to negotiate regarding waivers for its past covenant violations.
	On May 1, 2014, the Company entered into a three year revolving line of credit arrangement with Middlesex Savings Bank (“Middlesex”) for up to $4.0 million with the amount available for advances determined monthly based on eligible billed and unbilled accounts receivable and inventory. The line of credit is secured by substantially all the Company’s assets. Upon the closing of the loan, the Company repaid the approximately $1.8 million owed the senior lender and the $600,000 of accrued interest due the subordinated lender through April 30, 2014. The subordinated lender issued a waiver to the Company for prior covenant violations. As a result, the Company is no longer in default of any of its loan obligations and has reclassified the subordinated debt to a long term liability based on its terms.
	The Company considers events or transactions that have occurred after the unaudited consolidated balance sheet date of June 30, 2014, but prior to the filing of the unaudited consolidated financial statements with the SEC on this Form 10-Q, to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure, as applicable. Subsequent events have been evaluated through the date of the filing of this Quarterly Report on Form 10-Q with the SEC.

Formation_of컞Technologie

Formation of Xcede Technologies, Inc. Joint Venture	9 Months Ended
	Jun. 30, 2014
Equity Method Investments and Joint Ventures [Abstract]	'
Equity Method Investments and Joint Ventures Disclosure [Text Block]	'
	Note 2 – Formation of Xcede Technologies, Inc. Joint Venture
	On or about October 1, 2013, the Company formed Xcede Technologies, Inc. (“Xcede”), a joint venture with Mayo Clinic, in order to spin out and separately fund the development of its tissue sealant technology which formerly comprised the majority of its Biomedical segment. Xcede had received a total of approximately $800,000 in funding as of June 30, 2014 in the form of Convertible Notes from individual investors including certain directors of the Company. The notes accrue interest at 5%. Upon the closing of a capital stock financing by Xcede, the outstanding principal amount of the notes plus all accrued but unpaid interest on the notes will be converted into shares of the same capital stock sold in the capital stock financing at a 20% discount to the price per share of that capital stock financing. Alternatively, at any time prior to a capital stock financing the note holders can convert at their option into common stock of Xcede based on a $5.0 million valuation.
	Xcede is continuing its fund raising efforts as it will require additional funding in connection with human trials expected to commence in the Fall of 2014.
	Xcede’s common stock is 90% owned by Dynasil Biomedical. Xcede is a subsidiary of Dynasil Biomedical and Dynasil, and is, therefore, included in the Company’s consolidated balance sheet, results of operations and cash flows. Dynasil holds a majority of the seats on Xcede’s board of directors.

Acquisitions_and_Divestitures

Acquisitions and Divestitures	9 Months Ended
	Jun. 30, 2014
Business Combinations [Abstract]	'
Business Combination Disclosure [Text Block]	'
	Note 3 – Acquisitions and Divestitures
	On June 26, 2014, Dynasil and its wholly owned subsidiary Evaporated Metal Films Corp., a New York corporation (“EMF”) completed the acquisition of substantially all of the assets of DichroTec Thin Films, LLC (“DichroTec”), a New York limited liability company and manufacturer of optical thin film coatings.
	Pursuant to the Asset Purchase Agreement (the “APA”) by and among Dynasil, EMF, DichroTec and Syncrolite, LLC, a Texas limited liability company and the owner of DichroTec, EMF acquired substantially all of the assets of DichroTec for approximately $500,000 in cash and 700,000 shares of Dynasil Common Stock for a total purchase price of approximately $1.7 million. The APA contains customary representations, warranties, covenants and indemnification provisions for these types of transactions. The Company has not completed the allocation of the purchase price to the assets purchased which consist primarily of machinery and equipment, inventory and customer lists, in this filing it is all included in machinery and equipment. DichroTec reported unaudited revenue of approximately $1.9 million for the twelve months ended December 31, 2013.
	On November 7, 2013, the Company sold its Lead Paint detector business to Protec Instrument Corporation (“Protec”), a wholly owned subsidiary of Laboratoires Protec S.A., a French corporation and former European distributor of the Company’s lead paint detector products. The sales price totaled approximately $1.2 million, including the assumption of certain liabilities by Protec. The transaction also resulted in payment to the Company of approximately $500,000 in satisfaction of outstanding accounts receivable. The Company used $1.2 million of the proceeds from the sale to reduce its bank indebtedness.
	On December 23, 2013, the Company sold its Gamma Medical Probe business to Dilon Technologies, Inc., a Delaware corporation (“Dilon”), for $3.5 million, the assumption of certain liabilities of the Company, and a possible contingent payment. The Agreement also provided for $250,000 of the proceeds to be deposited in escrow for a year, which amount is included in accounts receivable in the Consolidated Balance Sheet. The Agreement contains customary representations, warranties, covenants and indemnification provisions. The Company used $2.8 million of the proceeds from the sale to reduce its bank indebtedness.
	In connection with the sales of the businesses discussed above, the Company recorded a gain of $1.2 million which is included in Income from Operations in the three months ended December 31, 2013. The businesses sold constituted substantially all of Instruments segment but did not constitute a component of the business, and therefore did not qualify to be reported as discontinued operations. The assets held for sale at September 30, 2013 included fixed assets, inventory, and intangible customer assets totaling $2.9 million offset by customer deposits of approximately $100,000.

Inventories

Inventories	9 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 4 - Inventories
	Inventories, net of reserves, consists of the following:
		June 30		September 30,
		2014		2013
	Raw Materials	$	1,610,235	$	2,132,962
	Work-in-Process		942,894		703,873
	Finished Goods		388,229		303,409
		$	2,941,358	$	3,140,244

Intangible_Assets

Intangible Assets	9 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Note 5 – Intangible Assets
	Intangible assets at June 30, 2014 and September 30, 2013 consist of the following:
		Useful				Gross			Accumulated
	June 30, 2014		Life (years)			Amount			Amortization			Net
	Acquired Customer Base			5 to 15		$	915,718		$	406,358		$	509,360
	Know How			15			539,405			204,882			334,523
	Trade Names			Indefinite			356,297			-			356,297
	Biomedical Technologies			5			260,000			126,667			133,333
						$	2,071,420		$	737,907		$	1,333,513
			Useful		Gross			Accumulated
	30-Sep-13		Life (years)		Amount			Amortization			Net
	Acquired Customer Base		5 to 15		$	5,145,638		$	2,645,715		$	2,499,923
	Know How		15			512,000			179,283			332,717
	Trade Names		15 or Indefinite			547,802			75,856			471,946
	Biomedical Technologies		5			300,000			120,003			179,997
					$	6,505,440		$	3,020,857		$	3,484,583
	Amortization expense for the three months ended June 30, 2014 and 2013 was $44,130 and $170,304, respectively. Amortization expense for the nine months ended June 30, 2014 and 2013 was $132,686 and $495,079, respectively. Estimated amortization expense for each of the next five fiscal years is as follows:
			2014 (3 months)			2015			2016			2017		2018		Thereafter		Total
	Acquired Customer Base		$	19,988		$	79,952		$	79,952		$	79,952	$	79,952	$	169,564	$	509,360
	Know How			8,534			34,133			34,133			34,133		34,133		189,457		334,523
	Biomedical Technologies			15,000			60,000			58,333			-		-		-		133,333
			$	43,522		$	174,085		$	172,418		$	114,085	$	114,085	$	359,021	$	977,216

Goodwill

Goodwill	9 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill Disclosure [Text Block]	'
	Note 6 – Goodwill
	Goodwill is subject to an annual impairment test. The Company considers many factors which may indicate the requirement to perform additional, interim impairment tests. These include:
		·	A significant adverse long term outlook for any of its industries;
		·	An adverse finding or rejection from a regulatory body involved in new product regulatory approvals;
		·	Failure of an anticipated commercialization of a product or product line;
		·	Unanticipated competition or the introduction of a disruptive technology;
		·	The testing for recoverability under the Impairment or Disposal of Long-Lived Assets Subsections of Subtopic 360-10 of a significant asset group within a reporting unit;
		·	A loss of key personnel; and
		·	An expectation that a reporting unit carrying goodwill, or a significant portion of a reporting unit, will be sold or otherwise disposed of.
	There were no changes, aside from foreign exchange rate fluctuations, in the carrying value of goodwill during the three and nine months ended June 30, 2014.

Earnings_Loss_Per_Common_Share

Earnings (Loss) Per Common Share	9 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 7 – Earnings (Loss) Per Common Share
	Basic earnings (loss) per common share is computed by dividing the net income applicable or loss attributable to common shares by the weighted average number of common shares. Diluted earnings per common share adjusts basic earnings per share for the effects of common stock options, common stock warrants, convertible preferred stock and other potential dilutive common shares outstanding during the periods.
	For purposes of computing diluted earnings per share for the three and nine months ended June 30, 2014 and 2013, no common stock options were included in the calculation of dilutive shares as all of the 630,532 common stock options outstanding had exercise prices above the current quarterly average market price per share and their inclusion is anti-dilutive. Additionally, for the three and nine months ended June 30, 2013, no common share equivalents related to stock options or unvested restricted stock were included in the calculation of dilutive shares, since there was a loss from continuing operations and the inclusion of common share equivalents would have been anti-dilutive.
	The computation of the weighted shares outstanding for the three months ended June 30 is as follows:
		June 30, 2014			June 30, 2013
	Weighted average shares outstanding
	Basic			15,280,607		14,859,899
	Effect of dilutive securities
	Stock Options			-		-
	Restricted Stock			18,815		-
	Dilutive Average Shares Outstanding			15,299,422		14,859,899
	The computation of the weighted shares outstanding for the nine months ended June 30 is as follows:
			June 30, 2014		June 30, 2013
	Weighted average shares outstanding
	Basic		15,134,377		14,767,401
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		11,262		-
	Dilutive Average Shares Outstanding		15,145,639		14,767,401

Stock_Based_Compensation

Stock Based Compensation	9 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 8 - Stock Based Compensation
	The fair value of the stock options granted is estimated at the date of grant using the Black-Scholes option pricing model.
	A summary of stock option activity for the nine months ended June 30, 2014 and 2013 is presented below:
		Options		Weighted Average			Weighted Average
		Outstanding		Exercise Price per			Remain Contractual
				Share			Term (in Years)
	Balance at September 30, 2013	630,532		$	3.33		1.06
	Outstanding and exercisable at September 30, 2013	630,532		$	3.33		1.06
	Granted	-			-
	Exercised	-			-
	Cancelled	-			-
	Balance at June 30, 2014	630,532		$	3.33		0.31
	Outstanding and exercisable at June 30, 2014	630,532		$	3.33		0.31
			Options		Weighted Average		Weighted Average
			Outstanding		Exercise Price per		Remain Contractual
					Share		Term (in Years)
	Balance at September 30, 2012		794,483		$	3.34		1.75
	Outstanding and exercisable at September 30, 2012		794,483		$	3.34		1.75
	Granted		-			-
	Exercised		-			-
	Cancelled		-163,951		$	3.39
	Balance at June 30, 2013		630,532		$	3.33		1.31
	Outstanding and exercisable at June 30, 2013		630,532		$	3.33		1.31
	A summary of restricted stock activity for the nine months ended June 30, 2014 and 2013 is presented below:
	Restricted Stock Activity for the Nine	Shares			Weighted-Average
	Months ended June 30, 2014				Grant-Date Fair Value
	Nonvested at September 30, 2013		423,168		$	0.74
	Granted		6,000		$	1.36
	Vested		-371,168		$	0.7
	Cancelled		-		$	-
	Nonvested at June 30, 2014		58,000		$	1.07
	Restricted Stock Activity for the Nine	Shares			Weighted-Average
	Months ended June 30, 2013				Grant-Date Fair Value
	Nonvested at September 30, 2012		127,834		$	1.92
	Granted		404,000		$	0.67
	Vested		-72,166		$	1.44
	Cancelled		-20,000		$	4.02
	Nonvested at June 30, 2013		439,668		$	0.76
	Stock Compensation Expense for the nine months ended June 30, 2014 and 2013 is as follows:
		Three Months Ended			Three Months Ended
	Stock Compensation Expense	June 30, 2014			June 30, 2013
	Stock Grants	$	111,510		$	48,125
	Restricted Stock Grants		51,014			41,576
	Option Grants		-			-
	Employee Stock Purchase Plan		590			843
	Total	$	163,114		$	90,544
		Nine Months Ended			Nine Months Ended
	Stock Compensation Expense	30-Jun-14			30-Jun-13
	Stock Grants	$	212,762		$	180,647
	Restricted Stock Grants		187,716			107,270
	Option Grants		-			9,813
	Employee Stock Purchase Plan		1,861			2,912
	Total	$	402,339		$	300,642
	At June 30, 2014 there was approximately $63,000 in unrecognized stock compensation cost, which is expected to be recognized over a weighted average period of approximately six months.

Segment_Customer_and_Geographi

Segment, Customer and Geographical Reporting	9 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 9 – Segment, Customer and Geographical Reporting
	Segment Financial Information
	Dynasil’s business is comprised of four segments: contract research (“Contract Research”), optics (“Optics”), instruments (“Instruments”) and biomedical (“Biomedical”). Within these segments, there is a segregation of reportable units based upon the organizational structure used to evaluate performance and make decisions on resource allocation, as well as availability and materiality of separate financial results consistent with that structure. The Contract Research segment is one of the largest small business participants in U.S. government-funded research. The Optics segment manufactures optical materials, components and coatings. The Instruments segment manufactures specialized instruments used in various applications in the medical, industrial, and homeland security/defense sectors. The Biomedical segment, through Xcede Technologies, Inc., a majority owned, joint venture (“Xcede”), is focused on developing a tissue sealant technology for a wide spectrum of applications though no assurance can be given that this technology will become successfully commercialized.
	As discussed in Note 3, substantially all the operating assets of the Instruments segment were sold in the three months ended December 31, 2013.
	The Company’s segment information for the three months ended June 30, 2014 and 2013 is summarized below:
	Results of Operations for the Three Months Ended June 30,
	2014
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	5,460,853	$	5,172,217		$	-		$	7,457		$	10,640,527
	Gross Profit		2,121,495		1,778,695			-			7,457			3,907,647
	Impairment of goodwill		-		-			-			-			-
	Operating Income (Loss)		64,007		224,705			39,983			-172,509			156,186
	Depreciation and Amortization		70,149		189,381			-			15,000			274,530
	Capital expenditures		-		1,937,479			-			-			1,937,479
	Intangibles, Net		307,118		893,062			-			133,333			1,333,513
	Goodwill		4,938,625		1,393,771			-			-			6,332,396
	Total Assets	$	9,451,010	$	16,053,222		$	335,290		$	632,094		$	26,471,616
	Results of Operations for the Three Months Ended June 30,
	2013
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	5,933,085	$	3,860,648		$	1,498,609		$	30,000		$	11,322,342
	Gross Profit		2,514,235		1,372,490			783,225			30,000			4,699,950
	Impairment of goodwill & long-lived assets		-		-			-			-			-
	Operating Income (Loss)		22,869		25,402			-48,219			-215,559			-215,507
	Depreciation and Amortization		88,770		191,741			163,715			15,000			459,226
	Capital expenditures		-		206,898			-			-			206,898
	Intangibles, Net		332,800		848,046			2,230,334			194,997			3,606,177
	Goodwill		4,938,625		1,197,503			-			-			6,136,128
	Total Assets	$	13,562,650	$	8,780,459		$	5,142,707		$	262,955		$	27,748,771
	The Company’s segment information for the nine months ended June 30, 2014 and 2013 is summarized below:
	Results of Operations for the Nine Months Ended June 30,
	2014
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	16,915,355	$	14,059,393		$	772,578		$	11,186		$	31,758,512
	Gross Profit		7,092,752		5,295,215			317,908			11,186			12,717,061
	Impairment of goodwill		-		-			-			-			-
	Operating Income (Loss)		654,339		1,145,249			1,006,161			-568,120			2,237,629
	Depreciation and Amortization		209,645		550,989			2,003			46,666			809,303
	Capital expenditures		12,028		2,606,365			-			-			2,618,393
	Intangibles, Net		307,118		893,062			-			133,333			1,333,513
	Goodwill		4,938,625		1,393,771			-			-			6,332,396
	Total Assets	$	9,451,010	$	16,053,222		$	335,290		$	632,094		$	26,471,616
	Results of Operations for the Nine Months Ended June 30,
	2013
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	16,331,775	$	12,044,354		$	3,796,967		$	187,051		$	32,360,147
	Gross Profit		7,376,158		4,434,381			1,850,127			187,051			13,847,717
	Impairment of goodwill & long-lived assets		-		-			6,763,072			-			6,763,072
	Operating Income (Loss)		254,278		413,414			-7,774,714			-547,786			-7,654,808
	Depreciation and Amortization		231,189		562,065			491,147			45,000			1,329,401
	Capital expenditures		-1,095		416,580			7,092			-			422,577
	Intangibles, Net		332,800		848,046			2,230,334			194,997			3,606,177
	Goodwill		4,938,625		1,197,503			-			-			6,136,128
	Total Assets	$	13,562,650	$	8,780,459		$	5,142,707		$	262,955		$	27,748,771
	Customer Financial Information
	For the three and nine months ended June 30, 2014 and 2013, the top three customers for the Contract Research segment were various agencies of the U.S. Government. For the three months ended June 30, 2014 and 2013, these customers made up 68% and 58%, respectively, of Contract Research revenue. For the nine months ended June 30, 2014 and 2013, these customers made up 67% and 59%, respectively, of Contract Research revenue.
	For the three and nine months ended June 30, 2014, a single customer in the Optics segment made up 18% and 10%, respectively of the total segment revenue. For the three and nine months ended June 30, 2013, there was no customer in the Optics segment whose revenue represented more than 10% of the total segment revenue.
	For the three months ended June 30, 2014, there was no revenue in the Instruments segment. For the three months ended June 30, 2013, the top three customers for the Instruments segment made up 28% of Instruments revenue. For the nine months ended June 30, 2014 and 2013, the top three customers for the Instruments segment made up 24% and 28%, respectively, of Instruments revenue.
	For both the three and nine months ended June 30, 2014 and 2013, the Biomedical segment had one customer whose revenue represented 100% of the total segment revenue.
Geographic Financial Information
Revenue by geographic location in total and as a percentage of total revenue, for the three months ended June 30, 2014 and 2013 are as follows:
	Three Months Ended					Three Months Ended
	June 30, 2014					June 30, 2013
Geographic Location	Revenue		% of Total			Revenue			% of Total
United States	$	8,254,373		78	%	$	9,426,542			83	%
Europe		688,855		6	%		975,941			9	%
Other		1,697,299		16	%		919,859			8	%
	$	10,640,527		100	%	$	11,322,342			100	%
Revenue by geographic location in total and as a percentage of total revenue, for the nine months ended June 30, 2014 and 2013 are as follows:
	Nine Months Ended				Nine Months Ended
	June 30, 2014				June 30, 2013
Geographic Location	Revenue		% of Total		Revenue			% of Total
United States	$	25,783,653	81	%	$	26,493,062		82	%
Europe		2,363,255	8	%		2,711,944		8	%
Other		3,611,604	11	%		3,155,141		10	%
	$	31,758,512	100	%	$	32,360,147		100	%

Income_Taxes

Income Taxes	9 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Note 10 - Income Taxes
	Dynasil Corporation of America and its wholly-owned U.S. subsidiaries file a consolidated federal income tax return and various state returns. The Company’s U.K. subsidiary files tax returns in the U.K.
	The Company uses the asset and liability approach to account for income taxes. Under this approach, deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes and net operating loss and tax credit carry forwards. The amount of deferred taxes on these temporary differences is determined using the tax rates that are expected to apply to the period when the asset is realized or the liability is settled, as applicable, based on tax rates, and tax laws, in the respective tax jurisdiction then in effect.
	In assessing the ability to realize the net deferred tax assets, management considers various factors including taxable income in carryback years, future reversals of existing taxable temporary differences, tax planning strategies and projections of future taxable income, to determine whether it is more likely than not that some portion or all of the net deferred tax assets will not be realized. Based upon the Company’s recent losses and uncertainty of future profits, the Company has determined that the uncertainty regarding the realization of these assets is sufficient to warrant the need for a full valuation allowance against its U.S. net deferred tax assets.
	The Company applies the authoritative provisions related to accounting for uncertainty in income taxes. As required by these provisions, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more-likely-than-not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being reached upon ultimate settlement with the relevant tax authority. As of June 30, 2014 and September 30, 2013, the Company has no unrecorded liabilities for uncertain tax positions. Interest and penalty charges, if any, related to uncertain tax positions would be classified as income tax expense in the accompanying consolidated statement of operations. As of June 30, 2014 and September 30, 2013, the Company had no accrued interest or penalties related to uncertain tax positions. The Company currently has no federal or state tax examinations in progress.
	The effective tax rates were (152%) and (5%) for the three and nine months ended June 30, 2014, respectively, and 8% and 3% for the three and nine months ended June 30, 2013, respectively. The rates differ from the U.S. federal statutory income tax rate of 34% primarily due to a full valuation allowance against the Company’s U.S. deferred tax asset and the recognition of certain UK research tax credits.
	The Company files its tax returns as prescribed by the tax laws of the jurisdictions in which it operates. The Company’s tax filings for federal and state jurisdictions for the tax years beginning with 2010 are still subject to examination.

New_Senior_Debt_Agreement

New Senior Debt Agreement	9 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Debt Disclosure [Text Block]	'
	Note 11 – New Senior Debt Agreement
	On May 1, 2014, Dynasil entered into a loan and security agreement (the “Bank Loan Agreement”) and line of credit note (the “Note”) with Middlesex Savings Bank pursuant to which Middlesex agreed to provide up to $4 million, subject to the availability restrictions described below, under a revolving line of credit loan to Dynasil for general corporate purposes. The Bank Loan Agreement provides that the loan expires on May 1, 2017, at which time all outstanding principal and unpaid interest shall become due and payable. The Bank Loan Agreement and the Note are secured by (i) a security interest in substantially all of the Company’s personal property and (ii) a sixty-five percent (65%) of the Dynasil’s equity interests in its UK subsidiary, Hilger Crystals, Ltd. Under the note, the borrowing base is determined monthly based on eligible billed and unbilled accounts receivable and eligible inventory. The interest rate under the Note is equal the Prime Rate, but in no event less than 3.25%.
	The Bank Loan Agreement also contains other terms, conditions and provisions that are customary for commercial lending transactions of this sort. The Bank Loan Agreement requires Dynasil, at the close of each fiscal quarter, to maintain a Debt Service Coverage ratio, as defined, of at least 1.20 to 1.00 on a trailing four quarter basis.
	The Bank Loan Agreement provides for events of default customary for credit facilities of this type, including but not limited to non-payment, defaults on other debt, misrepresentation, breach of covenants, representations and warranties, insolvency and bankruptcy, change of management, as defined and the occurrence of a material adverse change, as defined. As a result of the material adverse change clause, the line of credit has been classified as a current liability in this filing.

Subsequent_Events

Subsequent Events	9 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 12 – Subsequent Events
	The Company has evaluated subsequent events through the date that the financial statements were released.

Inventories_Tables

Inventories (Tables)	9 Months Ended
	Jun. 30, 2014
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
	Inventories, net of reserves, consists of the following:
		June 30		September 30,
		2014		2013
	Raw Materials	$	1,610,235	$	2,132,962
	Work-in-Process		942,894		703,873
	Finished Goods		388,229		303,409
		$	2,941,358	$	3,140,244

Intangible_Assets_Tables

Intangible Assets (Tables)	9 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Finite-Lived Intangible Assets [Table Text Block]	'
	Intangible assets at June 30, 2014 and September 30, 2013 consist of the following:
		Useful				Gross			Accumulated
	June 30, 2014		Life (years)			Amount			Amortization			Net
	Acquired Customer Base			5 to 15		$	915,718		$	406,358		$	509,360
	Know How			15			539,405			204,882			334,523
	Trade Names			Indefinite			356,297			-			356,297
	Biomedical Technologies			5			260,000			126,667			133,333
						$	2,071,420		$	737,907		$	1,333,513
			Useful		Gross			Accumulated
	30-Sep-13		Life (years)		Amount			Amortization			Net
	Acquired Customer Base		5 to 15		$	5,145,638		$	2,645,715		$	2,499,923
	Know How		15			512,000			179,283			332,717
	Trade Names		15 or Indefinite			547,802			75,856			471,946
	Biomedical Technologies		5			300,000			120,003			179,997
					$	6,505,440		$	3,020,857		$	3,484,583
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Estimated amortization expense for each of the next five fiscal years is as follows:
			2014 (3 months)			2015			2016			2017		2018		Thereafter		Total
	Acquired Customer Base		$	19,988		$	79,952		$	79,952		$	79,952	$	79,952	$	169,564	$	509,360
	Know How			8,534			34,133			34,133			34,133		34,133		189,457		334,523
	Biomedical Technologies			15,000			60,000			58,333			-		-		-		133,333
			$	43,522		$	174,085		$	172,418		$	114,085	$	114,085	$	359,021	$	977,216

Earnings_Loss_Per_Common_Share1

Earnings (Loss) Per Common Share (Tables)	9 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The computation of the weighted shares outstanding for the three months ended June 30 is as follows:
		June 30, 2014			June 30, 2013
	Weighted average shares outstanding
	Basic			15,280,607		14,859,899
	Effect of dilutive securities
	Stock Options			-		-
	Restricted Stock			18,815		-
	Dilutive Average Shares Outstanding			15,299,422		14,859,899
	The computation of the weighted shares outstanding for the nine months ended June 30 is as follows:
			June 30, 2014		June 30, 2013
	Weighted average shares outstanding
	Basic		15,134,377		14,767,401
	Effect of dilutive securities
	Stock Options		-		-
	Restricted Stock		11,262		-
	Dilutive Average Shares Outstanding		15,145,639		14,767,401

Stock_Based_Compensation_Table

Stock Based Compensation (Tables)	9 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	'
	A summary of stock option activity for the nine months ended June 30, 2014 and 2013 is presented below:
		Options		Weighted Average			Weighted Average
		Outstanding		Exercise Price per			Remain Contractual
				Share			Term (in Years)
	Balance at September 30, 2013	630,532		$	3.33		1.06
	Outstanding and exercisable at September 30, 2013	630,532		$	3.33		1.06
	Granted	-			-
	Exercised	-			-
	Cancelled	-			-
	Balance at June 30, 2014	630,532		$	3.33		0.31
	Outstanding and exercisable at June 30, 2014	630,532		$	3.33		0.31
			Options		Weighted Average		Weighted Average
			Outstanding		Exercise Price per		Remain Contractual
					Share		Term (in Years)
	Balance at September 30, 2012		794,483		$	3.34		1.75
	Outstanding and exercisable at September 30, 2012		794,483		$	3.34		1.75
	Granted		-			-
	Exercised		-			-
	Cancelled		-163,951		$	3.39
	Balance at June 30, 2013		630,532		$	3.33		1.31
	Outstanding and exercisable at June 30, 2013		630,532		$	3.33		1.31
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
	A summary of restricted stock activity for the nine months ended June 30, 2014 and 2013 is presented below:
	Restricted Stock Activity for the Nine	Shares			Weighted-Average
	Months ended June 30, 2014				Grant-Date Fair Value
	Nonvested at September 30, 2013		423,168		$	0.74
	Granted		6,000		$	1.36
	Vested		-371,168		$	0.7
	Cancelled		-		$	-
	Nonvested at June 30, 2014		58,000		$	1.07
	Restricted Stock Activity for the Nine	Shares			Weighted-Average
	Months ended June 30, 2013				Grant-Date Fair Value
	Nonvested at September 30, 2012		127,834		$	1.92
	Granted		404,000		$	0.67
	Vested		-72,166		$	1.44
	Cancelled		-20,000		$	4.02
	Nonvested at June 30, 2013		439,668		$	0.76
Schedule Of Stock Compensation Expense [Table Text Block]	'
	Stock Compensation Expense for the nine months ended June 30, 2014 and 2013 is as follows:
		Three Months Ended			Three Months Ended
	Stock Compensation Expense	June 30, 2014			June 30, 2013
	Stock Grants	$	111,510		$	48,125
	Restricted Stock Grants		51,014			41,576
	Option Grants		-			-
	Employee Stock Purchase Plan		590			843
	Total	$	163,114		$	90,544
		Nine Months Ended			Nine Months Ended
	Stock Compensation Expense	30-Jun-14			30-Jun-13
	Stock Grants	$	212,762		$	180,647
	Restricted Stock Grants		187,716			107,270
	Option Grants		-			9,813
	Employee Stock Purchase Plan		1,861			2,912
	Total	$	402,339		$	300,642

Segment_Customer_and_Geographi1

Segment, Customer and Geographical Reporting (Tables)	9 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The Company’s segment information for the three months ended June 30, 2014 and 2013 is summarized below:
	Results of Operations for the Three Months Ended June 30,
	2014
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	5,460,853	$	5,172,217		$	-		$	7,457		$	10,640,527
	Gross Profit		2,121,495		1,778,695			-			7,457			3,907,647
	Impairment of goodwill		-		-			-			-			-
	Operating Income (Loss)		64,007		224,705			39,983			-172,509			156,186
	Depreciation and Amortization		70,149		189,381			-			15,000			274,530
	Capital expenditures		-		1,937,479			-			-			1,937,479
	Intangibles, Net		307,118		893,062			-			133,333			1,333,513
	Goodwill		4,938,625		1,393,771			-			-			6,332,396
	Total Assets	$	9,451,010	$	16,053,222		$	335,290		$	632,094		$	26,471,616
	Results of Operations for the Three Months Ended June 30,
	2013
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	5,933,085	$	3,860,648		$	1,498,609		$	30,000		$	11,322,342
	Gross Profit		2,514,235		1,372,490			783,225			30,000			4,699,950
	Impairment of goodwill & long-lived assets		-		-			-			-			-
	Operating Income (Loss)		22,869		25,402			-48,219			-215,559			-215,507
	Depreciation and Amortization		88,770		191,741			163,715			15,000			459,226
	Capital expenditures		-		206,898			-			-			206,898
	Intangibles, Net		332,800		848,046			2,230,334			194,997			3,606,177
	Goodwill		4,938,625		1,197,503			-			-			6,136,128
	Total Assets	$	13,562,650	$	8,780,459		$	5,142,707		$	262,955		$	27,748,771
	The Company’s segment information for the nine months ended June 30, 2014 and 2013 is summarized below:
	Results of Operations for the Nine Months Ended June 30,
	2014
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	16,915,355	$	14,059,393		$	772,578		$	11,186		$	31,758,512
	Gross Profit		7,092,752		5,295,215			317,908			11,186			12,717,061
	Impairment of goodwill		-		-			-			-			-
	Operating Income (Loss)		654,339		1,145,249			1,006,161			-568,120			2,237,629
	Depreciation and Amortization		209,645		550,989			2,003			46,666			809,303
	Capital expenditures		12,028		2,606,365			-			-			2,618,393
	Intangibles, Net		307,118		893,062			-			133,333			1,333,513
	Goodwill		4,938,625		1,393,771			-			-			6,332,396
	Total Assets	$	9,451,010	$	16,053,222		$	335,290		$	632,094		$	26,471,616
	Results of Operations for the Nine Months Ended June 30,
	2013
		Contract		Optics			Instruments			Biomedical			Total
		Research
	Revenue	$	16,331,775	$	12,044,354		$	3,796,967		$	187,051		$	32,360,147
	Gross Profit		7,376,158		4,434,381			1,850,127			187,051			13,847,717
	Impairment of goodwill & long-lived assets		-		-			6,763,072			-			6,763,072
	Operating Income (Loss)		254,278		413,414			-7,774,714			-547,786			-7,654,808
	Depreciation and Amortization		231,189		562,065			491,147			45,000			1,329,401
	Capital expenditures		-1,095		416,580			7,092			-			422,577
	Intangibles, Net		332,800		848,046			2,230,334			194,997			3,606,177
	Goodwill		4,938,625		1,197,503			-			-			6,136,128
	Total Assets	$	13,562,650	$	8,780,459		$	5,142,707		$	262,955		$	27,748,771
Schedule Of Segment Revenue By Geographical Location [Table Text Block]	'
	Revenue by geographic location in total and as a percentage of total revenue, for the three months ended June 30, 2014 and 2013 are as follows:
		Three Months Ended					Three Months Ended
		June 30, 2014					June 30, 2013
	Geographic Location	Revenue		% of Total			Revenue			% of Total
	United States	$	8,254,373		78	%	$	9,426,542			83	%
	Europe		688,855		6	%		975,941			9	%
	Other		1,697,299		16	%		919,859			8	%
		$	10,640,527		100	%	$	11,322,342			100	%
	Revenue by geographic location in total and as a percentage of total revenue, for the nine months ended June 30, 2014 and 2013 are as follows:
		Nine Months Ended				Nine Months Ended
		June 30, 2014				June 30, 2013
	Geographic Location	Revenue		% of Total		Revenue			% of Total
	United States	$	25,783,653	81	%	$	26,493,062		82	%
	Europe		2,363,255	8	%		2,711,944		8	%
	Other		3,611,604	11	%		3,155,141		10	%
		$	31,758,512	100	%	$	32,360,147		100	%

Basis_of_Presentation_and_Abil1

Basis of Presentation and Ability to Continue as a Going Concern (Details Textual) (New Bank [Member], USD $)	1 Months Ended
	Apr. 30, 2014	1-May-14
New Bank [Member]	'	'
Basis Of Presentation [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	'	$4,000,000
Line of Credit Facility, Periodic Payment	1,800,000	'
Line of Credit Facility, Increase, Accrued Interest	$600,000	'

Formation_of컞Technologie1

Formation of Xcede Technologies, Inc. Joint Venture (Details Textual) (USD $)	0 Months Ended
	Oct. 02, 2013	Jun. 30, 2014
Schedule of Equity Method Investments [Line Items]	'	'
Proceeds from Convertible Debt	$800,000	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Capital Stock Financing Discount Percentage	20.00%	'
Common Stock Valuation	$5,000,000	'
Equity Method Investment, Ownership Percentage	'	90.00%
Common Stock, Conversion Features	'any time prior to a capital stock financing the note holders can convert at their option into common stock of Xcede based on a $5.0 million valuation	'

Acquisitions_and_Divestitures_

Acquisitions and Divestitures (Details Texuals) (USD $)	3 Months Ended			9 Months Ended			12 Months Ended		1 Months Ended	0 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013	Jun. 26, 2014	Dec. 23, 2013	Nov. 07, 2013
						DichroTec [Member]	DichroTec [Member]	DichroTec [Member]	Dilon [Member]	Protec [Member]
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'
Payments to Acquire Businesses, Gross	'	'	'	$500,000	$0	$500,000	'	'	'	'
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	'	'	'	'	'	700,000	'	'	'	'
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	'	'	'	'	'	'	'	1,700,000	'	'
Revenue, Net, Total	10,640,527	'	11,322,342	31,758,512	32,360,147	'	1,900,000	'	'	'
Proceeds from Sales of Business, Affiliate and Productive Assets	'	'	'	'	'	'	'	'	3,500,000	1,200,000
Repayment of Accounts Receivable	'	'	'	'	'	'	'	'	'	500,000
Repayments of Other Debt	'	'	'	'	'	'	'	'	'	1,200,000
Escrow Deposit	'	'	'	'	'	'	'	'	250,000	'
Proceeds from (Repayments of) Debt	'	'	'	'	'	'	'	'	2,800,000	'
Gain (Loss) on Disposition of Business	'	1,200,000	'	'	'	'	'	'	'	'
Disposal Group, Including Discontinued Operation, Assets, Noncurrent	'	2,900,000	'	'	'	'	'	'	'	'
Customer Deposits, Noncurrent	'	$100,000	'	'	'	'	'	'	'	'

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Sep. 30, 2013
Inventory Current [Line Items]	'	'
Raw Materials	$1,610,235	$2,132,962
Work-in-Process	942,894	703,873
Finished Goods	388,229	303,409
Inventory, Net, Total	$2,941,358	$3,140,244

Intangible_Assets_Details

Intangible Assets (Details) (USD $)

Jun. 30, 2014

Sep. 30, 2013

Jun. 30, 2013

Jun. 30, 2014

Sep. 30, 2013

Jun. 30, 2014

Sep. 30, 2013

Jun. 30, 2014

Sep. 30, 2013

Jun. 30, 2014

Sep. 30, 2013

Sep. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Sep. 30, 2013

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Acquired Customer Base [Member]

Know How [Member]

Know How [Member]

Trade Names [Member]

Trade Names [Member]

Biomedical Technologies [Member]

Biomedical Technologies [Member]

Minimum [Member]

Minimum [Member]

Maximum [Member]

Maximum [Member]

Finite-Lived Intangible Assets [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Useful Life (years)

'

'

'

'

'

'5 years

'5 years

'15 years

'15 years

'15 years

'15 years

'15 years

'

'5 years

'5 years

Gross Amount

$2,071,420

$6,505,440

'

$915,718

$5,145,638

'

'

'

'

$539,405

$512,000

$547,802

$356,297

$260,000

$300,000

Accumulated Amortization

737,907

3,020,857

'

406,358

2,645,715

'

'

'

'

204,882

179,283

75,856

0

126,667

120,003

Net

$1,333,513

$3,484,583

$3,606,177

$509,360

$2,499,923

'

'

'

'

$334,523

$332,717

$471,946

$356,297

$133,333

$179,997

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Jun. 30, 2014
Finite-Lived Intangible Assets [Line Items]	'
2014 (3 months)	$43,522
2015	174,085
2016	172,418
2017	114,085
2018	114,085
Thereafter	359,021
Total	977,216
Acquired Customer Base [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
2014 (3 months)	19,988
2015	79,952
2016	79,952
2017	79,952
2018	79,952
Thereafter	169,564
Total	509,360
Know How [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
2014 (3 months)	8,534
2015	34,133
2016	34,133
2017	34,133
2018	34,133
Thereafter	189,457
Total	334,523
Biomedical Technologies [Member]	'
Finite-Lived Intangible Assets [Line Items]	'
2014 (3 months)	15,000
2015	60,000
2016	58,333
2017	0
2018	0
Thereafter	0
Total	$133,333

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization of Intangible Assets	$44,130	$170,304	$132,686	$495,079

Earnings_Loss_Per_Common_Share2

Earnings (Loss) Per Common Share (Details)	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Weighted average shares outstanding	'	'	'	'
Basic	15,280,607	14,859,899	15,134,377	14,767,401
Effect of dilutive securities	'	'	'	'
Dilutive Average Shares Outstanding	15,299,422	14,859,899	15,145,639	14,767,401
Stock Option [Member]	'	'	'	'
Effect of dilutive securities	'	'	'	'
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	0	0	0	0
Restricted Stock [Member]	'	'	'	'
Effect of dilutive securities	'	'	'	'
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	18,815	0	11,262	0

Earnings_Loss_Per_Common_Share3

Earnings (Loss) Per Common Share (Details Textual)	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Loss Per Common Share [Line Items]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	630,532	630,532	630,532	630,532

Stock_Based_Compensation_Detai

Stock Based Compensation (Details) (USD $)	9 Months Ended			12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Balance,Options Outstanding	630,532	794,483	'	794,483
Outstanding and exercisable,Options	630,532	794,483	'	794,483
Granted,Options Outstanding	0	'	'	0
Exercised,Options Outstanding	0	'	'	0
Cancelled, Options Outstanding	0	'	'	-163,951
Balance,Options Outstanding	630,532	'	'	630,532
Outstanding and exercisable,Options	630,532	'	'	630,532
Balance,Weighted Average Exercise Price per Share	$3.33	$3.34	'	$3.34
Outstanding and exercisable,Weighted Average Exercise Price per Share	$3.33	$3.34	'	$3.34
Granted,Weighted Average Exercise Price per Share	$0	'	'	$0
Exercised,Weighted Average Exercise Price per Share	$0	'	'	$0
Cancelled,Weighted Average Exercise Price per Share	$0	'	'	$3.39
Balance,Weighted Average Exercise Price per Share	$3.33	'	'	$3.33
Outstanding and exercisable,Weighted Average Exercise Price per Share	$3.33	'	'	$3.33
Balance,Weighted Average Remain Contractual Term (In Years)	'3 months 22 days	'1 year 22 days	'1 year 9 months	'1 year 3 months 22 days
Outstanding and exercisable options,Weighted Average Remain Contractual Term (In Years)	'3 months 22 days	'1 year 22 days	'1 year 9 months	'1 year 3 months 22 days

Stock_Based_Compensation_Detai1

Stock Based Compensation (Details 1) (USD $)	9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'
Shares Nonvested, Beginning Balance	423,168	127,834
Shares, Granted	6,000	404,000
Shares, Vested	-371,168	-72,166
Shares, Cancelled	0	-20,000
Shares, Nonvested, Ending Balance	58,000	439,668
Weighted-Average Grant-Date Fair Value, Nonvested, Beginning Balance	$0.74	$1.92
Weighted-Average Grant-Date Fair Value, Granted	$1.36	$0.67
Weighted-Average Grant-Date Fair Value, Vested	$0.70	$1.44
Weighted-Average Grant-Date Fair Value, Cancelled	$0	$4.02
Weighted-Average Grant-Date Fair Value, Nonvested, Ending Balance	$1.07	$0.76

Stock_Based_Compensation_Detai2

Stock Based Compensation (Details 2) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock Based Compensation [Line Items]	'	'	'	'
Stock Compensation Expense	$163,114	$90,544	$402,339	$300,642
Stock Grants [Member]	'	'	'	'
Stock Based Compensation [Line Items]	'	'	'	'
Stock Compensation Expense	111,510	48,125	212,762	180,647
Restricted Stock Grants [Member]	'	'	'	'
Stock Based Compensation [Line Items]	'	'	'	'
Stock Compensation Expense	51,014	41,576	187,716	107,270
Option Grants [Member]	'	'	'	'
Stock Based Compensation [Line Items]	'	'	'	'
Stock Compensation Expense	0	0	0	9,813
Employee Stock Purchase Plan [Member]	'	'	'	'
Stock Based Compensation [Line Items]	'	'	'	'
Stock Compensation Expense	$590	$843	$1,861	$2,912

Stock_Based_Compensation_Detai3

Stock Based Compensation (Details Textual) (USD $)	Jun. 30, 2014
Stock Based Compensation [Line Items]	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$63,000

Segment_Customer_and_Geographi2

Segment, Customer and Geographical Reporting (Details) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Sep. 30, 2013
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	$10,640,527	$11,322,342	$31,758,512	$32,360,147	'
Gross Profit	3,907,647	4,699,950	12,717,061	13,847,717	'
Impairment of goodwill	0	0	0	6,763,072	'
Operating Income (Loss)	156,186	-215,507	2,237,629	-7,654,808	'
Depreciation and Amortization	274,530	459,226	809,303	1,329,401	'
Capital expenditures	1,937,479	206,898	879,303	422,577	'
Intangibles, Net	1,333,513	3,606,177	1,333,513	3,606,177	3,484,583
Goodwill	6,332,396	6,136,128	6,332,396	6,136,128	6,240,983
Total Assets	26,471,616	27,748,771	26,471,616	27,748,771	26,677,226
Contract Research [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	5,460,853	5,933,085	16,915,355	16,331,775	'
Gross Profit	2,121,495	2,514,235	7,092,752	7,376,158	'
Impairment of goodwill	0	0	0	0	'
Operating Income (Loss)	64,007	22,869	654,339	254,278	'
Depreciation and Amortization	70,149	88,770	209,645	231,189	'
Capital expenditures	0	0	12,028	-1,095	'
Intangibles, Net	307,118	332,800	307,118	332,800	'
Goodwill	4,938,625	4,938,625	4,938,625	4,938,625	'
Total Assets	9,451,010	13,562,650	9,451,010	13,562,650	'
Optics [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	5,172,217	3,860,648	14,059,393	12,044,354	'
Gross Profit	1,778,695	1,372,490	5,295,215	4,434,381	'
Impairment of goodwill	0	0	0	0	'
Operating Income (Loss)	224,705	25,402	1,145,249	413,414	'
Depreciation and Amortization	189,381	191,741	550,989	562,065	'
Capital expenditures	1,937,479	206,898	2,606,365	416,580	'
Intangibles, Net	893,062	848,046	893,062	848,046	'
Goodwill	1,393,771	1,197,503	1,393,771	1,197,503	'
Total Assets	16,053,222	8,780,459	16,053,222	8,780,459	'
Instruments [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	0	1,498,609	772,578	3,796,967	'
Gross Profit	0	783,225	317,908	1,850,127	'
Impairment of goodwill	0	0	0	6,763,072	'
Operating Income (Loss)	39,983	-48,219	1,006,161	-7,774,714	'
Depreciation and Amortization	0	163,715	2,003	491,147	'
Capital expenditures	0	0	0	7,092	'
Intangibles, Net	0	2,230,334	0	2,230,334	'
Goodwill	0	0	0	0	'
Total Assets	335,290	5,142,707	335,290	5,142,707	'
Biomedical [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
Revenue	7,457	30,000	11,186	187,051	'
Gross Profit	7,457	30,000	11,186	187,051	'
Impairment of goodwill	0	0	0	0	'
Operating Income (Loss)	-172,509	-215,559	-568,120	-547,786	'
Depreciation and Amortization	15,000	15,000	46,666	45,000	'
Capital expenditures	0	0	0	0	'
Intangibles, Net	133,333	194,997	133,333	194,997	'
Goodwill	0	0	0	0	'
Total Assets	$632,094	$262,955	$632,094	$262,955	'

Segment_Customer_and_Geographi3

Segment, Customer and Geographical Reporting (Details 1) (USD $)	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue	$10,640,527	$11,322,342	$31,758,512	$32,360,147
% of Total	100.00%	100.00%	100.00%	100.00%
United State [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue	8,254,373	9,426,542	25,783,653	26,493,062
% of Total	78.00%	83.00%	81.00%	82.00%
Europe [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue	688,855	975,941	2,363,255	2,711,944
% of Total	6.00%	9.00%	8.00%	8.00%
Other Credit Derivatives [Member]	'	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'	'
Revenue	$1,697,299	$919,859	$3,611,604	$3,155,141
% of Total	16.00%	8.00%	11.00%	10.00%

Segment_Customer_and_Geographi4

Segment, Customer and Geographical Reporting (Details Textual)	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Three Customer [Member] | Sales Revenue, Net [Member]	'	'	'	'
Segment Reporting [Line Items]	'	'	'	'
Concentration Risk, Percentage	'	28.00%	24.00%	28.00%
Optics [Member]	'	'	'	'
Segment Reporting [Line Items]	'	'	'	'
Concentration Risk, Percentage	18.00%	'	10.00%	'
Biomedical Technologies [Member] | Customer One [Member]	'	'	'	'
Segment Reporting [Line Items]	'	'	'	'
Concentration Risk, Percentage	100.00%	100.00%	100.00%	100.00%
Customer Concentration Risk [Member]	'	'	'	'
Segment Reporting [Line Items]	'	'	'	'
Concentration Risk, Percentage	68.00%	58.00%	67.00%	59.00%

Income_Taxes_Details_Textual

Income Taxes (Details Textual)	3 Months Ended		9 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Tax [Line Items]	'	'	'	'
Effective Income Tax Rate Reconciliation, Percent, Total	152.00%	8.00%	5.00%	3.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	'	'	34.00%	'

New_Senior_Debt_Agreement_Deta

New Senior Debt Agreement (Details Texuals) (Revolving Credit Facility [Member], USD $)	9 Months Ended
In Millions, unless otherwise specified	Jun. 30, 2014
Revolving Credit Facility [Member]	'
Debt Instrument [Line Items]	'
Line of Credit Facility, Maximum Borrowing Capacity	$4
Debt Instrument, Collateral	'The Bank Loan Agreement and the Note are secured by (i) a security interest in substantially all of the Company’s personal property and (ii) a sixty-five percent (65%) of the Dynasil’s equity interests in its UK subsidiary, Hilger Crystals, Ltd.
Debt Instrument, Interest Rate, Effective Percentage	3.25%
Debt Instrument, Maturity Date	1-May-17
Debt Instrument, Covenant Description	'at least 1.20 to 1.00 on a trailing four quarter basis.